As an additional consideration, recent findings suggest that the use of new P2Y12 inhibitors instead of clopidogrel might further increase the effectiveness of DAPT in preventing cardioembolic stroke [21,22], thus further reducing the efficacy gap on this specific endpoint between OAC in the setting of TAT vs. DAPT when one of the new P2Y12 inhibitors is used. This evidence concerns the gene P2RY12 and cardioembolic stroke.